ELOX Stock Forecast & Price Target

Eloxx Pharma is a clinical-stage biopharmaceutical company, and has recently completed a financing and uplisting to the NASDAQ. Their flagship drug, exaluren, has shown promising results in a small study with three patients with Alport syndrome, reducing foot process effacement and width while also increasing Collagen IV expression. If successful, exaluren could capture as much as 50% of the US NMAS market, with peak US probability-adjusted annual sales of $425 million. Eloxx also has potential in the larger ADPKD market, with a POS of 35% and unadjusted sales potential of $1.4 billion if successful. The company currently has a positive outlook and will continue to develop exaluren in both indications, with Phase 2b data expected in mid-2027. Their current cash position of $65.7 million should sustain them until 2033, when they are expected to become profitable.

Eloxx Pharma is a clinical-stage company with a limited dataset for their lead candidate, exaluren, and faces potential questions around sampling bias and limited route of administration for the drug. Their current market projections are also based on assumptions of a high share of the market, despite the potential for generic competition once exclusivity is lost. With regulatory delays and poor commercial execution, we believe there is significant downside risk for the company's valuation.